Wells Fargo Maintains Equal-Weight on Alnylam Pharmaceuticals, Raises Price Target to $233
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Tiago Fauth maintains an Equal-Weight rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and raises the price target from $207 to $233.
August 02, 2024 | 6:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wells Fargo analyst Tiago Fauth maintains an Equal-Weight rating on Alnylam Pharmaceuticals and raises the price target from $207 to $233.
The raised price target from $207 to $233 by Wells Fargo indicates a positive outlook on Alnylam Pharmaceuticals, which could lead to a short-term increase in stock price. However, the Equal-Weight rating suggests a balanced view, moderating the impact.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100